News

In a paper entitled “Targeted delivery of liquid micro volumes into the lung” published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a multidisciplinary team of researchers from Columbia University in New…

Researchers at Institut national de la santé et de la recherche médicale (INSERM) in France have learned one way to “fix” cells that have characteristics of cystic fibrosis. These cells, which had faulty CFTR channel proteins, were able to make more functional CFTR protein following treatment with tumor necrosis…

Several studies have recently been released looking at the use of dry mannitol powder in an inhalation device for the management of cystic fibrosis. One study, entitled “Optimising inhaled mannitol for cystic fibrosis in an adult population,” published in Breathe, explored the safety and…

In both adolescents and adults, nutritional status can play a major role in the rate of disease progression. Individuals with poor nutritional status and low weight retention are at a higher risk for worsening lung function and increased mortality. However, in light of a new study from Hospital Universitario Ramón…

Future Science Group (FSG), a progressive publisher focused on breakthrough medical, biotechnological, and scientific research, has announced publication of a special issue in Future Science OA, covering the rapidly evolving field of protein misfolding diseases — a category that includes Cystic Fibrosis, Alzheimer’s and Parkinson’s…

Treating the root cause of cystic fibrosis, rather than just the symptoms, may be an ideal approach to improving patient outcomes for people with the disease. Thanks to a new study conducted by scientists at Howard Hughes Medical Institute and University of Illinois at Urbana-Champaign, a treatment strategy based on this concept may…

The pathogen Pseudomonas aeruginosa is the most common infectious agent that affects cystic fibrosis patients and leads to chronic pulmonary infection and progressive lung damage. Researchers have been hard at work developing a vaccine against Pseudomonas aeruginosa to administer to cystic fibrosis patients to prevent colonization and subsequent lung damage,…

The first-of-its kind Kitabis Pak, a co-packaged generic tobramycin inhalation solution and PARI LC PLUS Nebulizer indicated for cystic fibrosis, was recently named one of 2014’s 10 notable drug-device approvals. The list is currently published in this month’s issue of Drug Development & Delivery. The Kitabis…

Raptor Pharmaceutical Corp., recently announced it has reached an agreement with Tripex Pharmaceuticals over the rights to Quinsair, a first-of-its-kind inhaled fluoroquinolone indicated for chronic respiratory infections caused by Psuedomonas aeruginosa in adult cystic fibrosis patients. Quinsair was granted marketing authorization by the European Commission and Health Canada earlier this year.

Newly found workings of Pseudomonas aeruginosa may explain why certain medications are only modestly effective in patients with cystic fibrosis. A group of researchers led by Dr. Pradeep Singh and Dr. Peter Jorth at the University of Washington School of Medicine discovered that when P. aeruginosa infects cystic fibrosis patients’…